vs
Side-by-side financial comparison of AES Corporation (AES) and Biogen (BIIB). Click either name above to swap in a different company.
AES Corporation is the larger business by last-quarter revenue ($3.1B vs $2.5B, roughly 1.3× Biogen). Biogen runs the higher net margin — 12.9% vs 10.3%, a 2.6% gap on every dollar of revenue. On growth, AES Corporation posted the faster year-over-year revenue change (4.7% vs 2.0%). Biogen produced more free cash flow last quarter ($594.3M vs $-47.0M). Over the past eight quarters, Biogen's revenue compounded faster (0.3% CAGR vs 0.3%).
The AES Corporation is an American utility and power generation company. It owns and operates power plants, which it uses to generate and sell electricity to end users and intermediaries like utilities and industrial facilities. AES, headquartered in Arlington, Virginia, is one of the world's leading power companies, generating and distributing electric power in 15 countries and employing 10,500 people worldwide. AES Corporation is a global Fortune 500 power company.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
AES vs BIIB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.1B | $2.5B |
| Net Profit | $320.0M | $319.5M |
| Gross Margin | 18.8% | — |
| Operating Margin | -8.7% | — |
| Net Margin | 10.3% | 12.9% |
| Revenue YoY | 4.7% | 2.0% |
| Net Profit YoY | -42.9% | 32.8% |
| EPS (diluted) | $0.45 | $2.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.5B | ||
| Q4 25 | $3.1B | $2.3B | ||
| Q3 25 | $3.4B | $2.5B | ||
| Q2 25 | $2.9B | $2.6B | ||
| Q1 25 | $2.9B | $2.4B | ||
| Q4 24 | $3.0B | $2.5B | ||
| Q3 24 | $3.3B | $2.5B | ||
| Q2 24 | $2.9B | $2.5B |
| Q1 26 | — | $319.5M | ||
| Q4 25 | $320.0M | $-48.9M | ||
| Q3 25 | $639.0M | $466.5M | ||
| Q2 25 | $-95.0M | $634.8M | ||
| Q1 25 | $46.0M | $240.5M | ||
| Q4 24 | $560.0M | $266.7M | ||
| Q3 24 | $502.0M | $388.5M | ||
| Q2 24 | $185.0M | $583.6M |
| Q1 26 | — | — | ||
| Q4 25 | 18.8% | 78.3% | ||
| Q3 25 | 21.9% | 73.4% | ||
| Q2 25 | 15.9% | 77.1% | ||
| Q1 25 | 15.1% | 74.1% | ||
| Q4 24 | 14.2% | 76.2% | ||
| Q3 24 | 22.0% | 74.1% | ||
| Q2 24 | 18.8% | 77.8% |
| Q1 26 | — | — | ||
| Q4 25 | -8.7% | -2.5% | ||
| Q3 25 | 9.8% | 22.0% | ||
| Q2 25 | 1.4% | 28.1% | ||
| Q1 25 | -0.8% | 12.8% | ||
| Q4 24 | 12.3% | 11.9% | ||
| Q3 24 | 10.0% | 18.3% | ||
| Q2 24 | -2.6% | 28.3% |
| Q1 26 | — | 12.9% | ||
| Q4 25 | 10.3% | -2.1% | ||
| Q3 25 | 19.1% | 18.4% | ||
| Q2 25 | -3.3% | 24.0% | ||
| Q1 25 | 1.6% | 9.9% | ||
| Q4 24 | 18.9% | 10.9% | ||
| Q3 24 | 15.3% | 15.8% | ||
| Q2 24 | 6.3% | 23.7% |
| Q1 26 | — | $2.15 | ||
| Q4 25 | $0.45 | $-0.35 | ||
| Q3 25 | $0.89 | $3.17 | ||
| Q2 25 | $-0.15 | $4.33 | ||
| Q1 25 | $0.07 | $1.64 | ||
| Q4 24 | $0.78 | $1.82 | ||
| Q3 24 | $0.71 | $2.66 | ||
| Q2 24 | $0.27 | $4.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.6B | $3.4B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.1B | $18.7B |
| Total Assets | $51.8B | $29.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $3.4B | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.8B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $1.8B | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $6.3B | ||
| Q3 25 | — | $6.3B | ||
| Q2 25 | — | $6.3B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | — | $6.3B | ||
| Q3 24 | — | $4.5B | ||
| Q2 24 | — | $6.3B |
| Q1 26 | — | $18.7B | ||
| Q4 25 | $4.1B | $18.3B | ||
| Q3 25 | $3.9B | $18.2B | ||
| Q2 25 | $3.4B | $17.6B | ||
| Q1 25 | $3.5B | $17.0B | ||
| Q4 24 | $3.6B | $16.7B | ||
| Q3 24 | $3.3B | $16.4B | ||
| Q2 24 | $3.1B | $15.9B |
| Q1 26 | — | $29.5B | ||
| Q4 25 | $51.8B | $29.4B | ||
| Q3 25 | $50.8B | $29.2B | ||
| Q2 25 | $48.5B | $28.3B | ||
| Q1 25 | $48.6B | $28.0B | ||
| Q4 24 | $47.4B | $28.0B | ||
| Q3 24 | $50.1B | $28.3B | ||
| Q2 24 | $47.7B | $26.8B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.28× | ||
| Q2 24 | — | 0.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.5B | — |
| Free Cash FlowOCF − Capex | $-47.0M | $594.3M |
| FCF MarginFCF / Revenue | -1.5% | 24.0% |
| Capex IntensityCapex / Revenue | 49.5% | — |
| Cash ConversionOCF / Net Profit | 4.65× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-1.6B | $2.4B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $511.9M | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $976.0M | $160.9M | ||
| Q1 25 | $545.0M | $259.3M | ||
| Q4 24 | $1.1B | $760.9M | ||
| Q3 24 | $985.0M | $935.6M | ||
| Q2 24 | $392.0M | $625.8M |
| Q1 26 | — | $594.3M | ||
| Q4 25 | $-47.0M | $468.0M | ||
| Q3 25 | $-511.0M | $1.2B | ||
| Q2 25 | $-356.0M | $134.3M | ||
| Q1 25 | $-709.0M | $222.2M | ||
| Q4 24 | $-639.0M | $721.6M | ||
| Q3 24 | $-847.0M | $900.6M | ||
| Q2 24 | $-1.3B | $592.3M |
| Q1 26 | — | 24.0% | ||
| Q4 25 | -1.5% | 20.5% | ||
| Q3 25 | -15.2% | 48.4% | ||
| Q2 25 | -12.5% | 5.1% | ||
| Q1 25 | -24.2% | 9.1% | ||
| Q4 24 | -21.6% | 29.4% | ||
| Q3 24 | -25.8% | 36.5% | ||
| Q2 24 | -43.9% | 24.0% |
| Q1 26 | — | — | ||
| Q4 25 | 49.5% | 1.9% | ||
| Q3 25 | 54.0% | 1.8% | ||
| Q2 25 | 46.7% | 1.0% | ||
| Q1 25 | 42.9% | 1.5% | ||
| Q4 24 | 58.3% | 1.6% | ||
| Q3 24 | 55.7% | 1.4% | ||
| Q2 24 | 57.3% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.65× | — | ||
| Q3 25 | 2.03× | 2.73× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | 11.85× | 1.08× | ||
| Q4 24 | 1.94× | 2.85× | ||
| Q3 24 | 1.96× | 2.41× | ||
| Q2 24 | 2.12× | 1.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AES
| Electric Distribution | $1.0B | 33% |
| Regulated Revenue | $1.0B | 33% |
| Renewables | $786.0M | 25% |
| AES Andes | $225.0M | 7% |
| Corporate Other And Other | $38.0M | 1% |
| Other Expense | $10.0M | 0% |
BIIB
| Product revenue, net | $1.8B | 71% |
| Royalty revenue on sales of OCREVUS | $317.2M | 13% |
| Contract manufacturing, royalty and other revenue | $246.9M | 10% |
| Biogen's share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO | $94.7M | 4% |
| Alzheimer's collaboration Revenue | $59.5M | 2% |
| Other revenue from anti-CD20 therapeutic programs | $7.2M | 0% |
